Adocia : M1Pram is the focus of attention in the short term
>Agreement with Sanofi for M1Pram as main short-term catalyst - This week we had the opportunity to accompany Adocia on a road show with Olivier Soula (CEO) and Valérie Danaguezian (CFO). This was an opportunity for the biotech's management to review the progress of the various compounds in its pipeline and to take stock of the catalysts ahead for the company. The potential conclusion of a global partnership agreement with Sanofi for M1Pram will be at the heart of the...ADOCIA is a biotechnology company based in France. Co. specializes in the development of formulations for already-approved therapeutic proteins with a primary focus on insulins and treatments for diabetic foot ulcers. Co.'s biotherapy products are used in tissue regeneration and for treating chronic diseases. Co.'s proprietary BioChaperone® technological platform is designed to enhance the effectiveness and safety of therapeutic proteins in areas such as wound Healing, diabetes, ulcers and monoclonal antibody creation. Co. also maintains activities in the formulation of monoclonal antibodies for the treatment of various chronic pathologies (oncology, inflammation, etc.).
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.